Office of Technology Transfer – University of Michigan

Discovery of novel (quinolin-8-yl) nicotinamides for pancreatic cancer

Technology #6694

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Nouri Neamati
Managed By
Stefan Koehler
Senior Licensing Specialist, Health Technologies 734-764-4290
Patent Protection
US Patent Pending

Pancreatic cancer has a 5-year survival rate under 5% and is the deadliest cancer. Early- stage disease is asymptomatic, therefore, advanced late-stage disease is more frequently diagnosed. Pancreatic cancer typically shows resistance to chemotherapy and other therapeutics resulting in poor prognosis. Some patients are eligible for surgery but relapse often arises. In addition, 80% of advanced pancreatic cancer patients are not eligible for surgery and no current treatment has demonstrated long-term benefit for these patients. Novel therapies for pancreatic cancer are urgently needed.

Novel therapeutic for pancreatic cancer

A novel class of compounds for pancreatic cancer was identified in a phenotypic screen of 20,000 small molecules. This class of compounds shows efficacy in several pancreatic cell lines and in mouse xenograft models. The molecular target is unknown but changes in the expression of genes associated with the stress response pathway and autophagy were affected upon treatment, suggesting a possible mechanism of action.


  • Treatment for pancreatic cancer


  • Potentially new mechanism of action